ARA 290 vs LL-37
Updated November 4, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of ARA 290 and LL-37 (also searched as LL-37 vs ARA 290) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
ARA 290 centers on neuro, while LL-37 leans toward healing. On indexed research, LL-37 is ahead (ARA 290: 32 studies, Human evidence; LL-37: 34, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •ARA 290 is strongest for neuro; LL-37 for healing.
- •Evidence: ARA 290 Human evidence (32 studies) vs LL-37 Human evidence (34).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
ARA 290 vs LL-37: side-by-side
| Metric | ARA 290 | LL-37 |
|---|---|---|
| Class | Neuro | Immune |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 32 | 34 |
| Research level | Preclinical | Well Studied |
| Strongest effect | Neuro & mood | Healing & recovery |
| Healing & recovery | 4.0 | 5.0▲ |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 2.0▲ | 0.0 |
| Neuro & mood | 5.0▲ | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 3.0 | 4.0▲ |
| Skin & aesthetics | 0.0 | 2.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | ARA 290 | LL-37 |
|---|---|---|
| Mechanism | Modulates macrophage activity and promotes anti-inflammatory cytokine release | Disrupts microbial membranes, modulates immune responses |
| Route | Subcutaneous injection | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is ARA 290?
ARA 290, also known as a peptide derived from the erythropoietin (EPO) molecule, has garnered attention for its potential therapeutic applications, particularly in the context of nerve regeneration and protection. The peptide is designed to mimic some of the beneficial effects of EPO without eliciting the same erythropoietic activity, which can lead to unwanted side effects such as increased blood viscosity and hypertension.
Full ARA 290 profile, mechanism & studies →What is LL-37?
LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in the innate immune response. It is produced by various cells, including epithelial cells and neutrophils, and exhibits a broad spectrum of biological activities, including antimicrobial, immunomodulatory, and wound healing properties. LL-37 interacts with a variety of pathogens, including bacteria, viruses, and fungi, contributing to the host's defense mechanisms.
Full LL-37 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | LL-37 | 5.0/5 effect signal |
| Metabolic | ARA 290 | 2.0/5 effect signal |
| Neuro | ARA 290 | 5.0/5 effect signal |
| Inflammation | LL-37 | 4.0/5 effect signal |
| Skin | LL-37 | 2.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack ARA 290 and LL-37?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
ARA 290 vs LL-37: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
ARA 290 has 32 approved studies indexed (Human evidence), and LL-37 has 34 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is ARA 290 or LL-37 better?
It depends on your goal. ARA 290 is strongest for neuro; LL-37 for healing. LL-37 has more indexed studies (34). See the goal-by-goal breakdown above.
Is ARA 290 or LL-37 better for weight loss?
ARA 290 shows the stronger metabolic & appetite profile (2.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Which has more research, ARA 290 or LL-37?
ARA 290 has 32 approved studies indexed (Human evidence); LL-37 has 34 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack ARA 290 and LL-37?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of ARA 290 vs LL-37?
ARA 290: no community-reported effects logged yet. LL-37: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is ARA 290 or LL-37 FDA-approved?
ARA 290 is a research-use compound and is not FDA-approved. LL-37 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is LL-37 better than ARA 290?
For healing, LL-37 has the edge; for neuro, ARA 290 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
ARA 290 and LL-37 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed November 4, 2026.